跳转至内容
Merck
CN

V4890

Sigma-Aldrich

Vindesine sulfate salt hydrate

≥95% (HPLC)

别名:

3-(Aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine sulfate salt hydrate, Desacetylvinblastine amide sulfate salt hydrate

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C43H55N5O7 · H2SO4 · xH2O
化学文摘社编号:
分子量:
852.00 (anhydrous basis)
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

方案

≥95% (HPLC)

表单

powder

颜色

off-white to light yellow

溶解性

deionized water: ≥50 mg/mL

创始人

Eli Lilly

储存温度

−20°C

SMILES字符串

O.OS(O)(=O)=O.CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C)[C@H]7[C@](O)([C@H](O)[C@]8(CC)C=CC[N@H]9CC[C@]67[C@H]89)C(N)=O)C1

InChI

1S/C43H55N5O7.H2O4S.H2O/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50;1-5(2,3)4;/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50);(H2,1,2,3,4);1H2/t25-,34+,35-,36-,39+,40-,41-,42+,43+;;/m1../s1

InChI key

TUDLKTILIBRXNU-RIHOAIHNSA-N

生化/生理作用

Microtubule inhibitor
Microtubule inhibitor. Vindesine binds to and stabilizes tubulin, thereby preventing tubulin polymerization, preventing mitosis, and arresting cells in metaphase.

特点和优势

This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Yukitaka Nakano et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 132(6), 727-732 (2012-06-13)
This paper reports a specific and sensitive enzyme-linked immunosorbent assay (ELISA) for pharmacokinetic studies of vindesine (VDS). Anti-VDS antibody was obtained by immunizing rabbits with VDS conjugated with bovine serum albumin using N-[β-(4-diazophenyl) ethyl] maleimide as a heterobifunctional coupling agent.
Teodoro Chisesi et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(32), 4227-4233 (2011-10-13)
The Intergruppo Italiano Linfomi HD9601 trial compared doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) versus doxorubicin, vinblastine, mechloretamine, vincristine, bleomycin, etoposide, and prednisone (Stanford V [StV]) versus the combination of mechlorethamine, vincristine, procarbazine, prednisone (MOPP) with epidoxorubicin, bleomycin, vinblastine (EBV), lomustine
Intensified chemotherapy for diffuse large B-cell lymphomas.
Julie M Vose
Lancet (London, England), 378(9806), 1828-1829 (2011-11-29)
Olivier Fitoussi et al.
Haematologica, 96(8), 1136-1143 (2011-05-07)
As rituximab combined with CHOP improves complete remission and overall survival in diffuse large B-cell lymphoma, intensified chemotherapy followed by autologous stem-cell transplantation has also been advocated for high-risk patients. The aim of this study was to establish whether or
Christian Récher et al.
Lancet (London, England), 378(9806), 1858-1867 (2011-11-29)
The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy regimens. We aimed to assess, in patients aged 18-59 years, the potential survival benefit provided by a dose-intensive

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持